Literature DB >> 7683001

Induction of early gene expression in murine macrophages by synthetic lipid A analogs with differing endotoxic potentials.

P Y Perera1, C L Manthey, P L Stütz, J Hildebrandt, S N Vogel.   

Abstract

Numerous lipid A analogs have been synthesized in an attempt to dissociate endotoxic activities from beneficial immunomodulatory activities. In the present study, we have evaluated select lipid A analogs in macrophages for their ability to induce a panel of lipopolysaccharide (LPS)-inducible genes to gain insights into the molecular mechanisms which underlie endotoxicity. We evaluated three monosaccharide lipid A analogs: SDZ MRL 953, an agonist with an improved therapeutic margin over endotoxin; SDZ 281.288, a more toxic analog; and SDZ 880.431, an analog with proven LPS-inhibitory activity. In addition, three disaccharide lipid A analogs (i.e., lipid IVA, SDZ 880.611, and SDZ 880.924) that differ in acylation and phosphorylation patterns were also examined and compared with synthetic lipid A. With the exception of SDZ 880.431, each of these structurally diverse analogs was able to induce the complete panel of LPS-inducible genes, specifically genes which encode tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta, 75-kDa type 2 TNF receptor (D7), IP-10, D3, and D8. These results underscore that macrophage stimulation by lipid A analogs is permissive to considerable structural diversity. Structures with favorable therapeutic indices (SDZ MRL 953, SDZ 880.611, and SDZ 880.924) were not different from structures with poor therapeutic indices (lipid A, lipid IVA, and SDZ 281.288) with regard to gene induction. Nonetheless, the nontoxic SDZ MRL 953 was approximately 1,000-fold less potent than synthetic lipid A at inducing TNF-alpha secretion, and perhaps this contributes to the lack of toxicity exhibited by this compound. The ability of compound SDZ 880.431 to inhibit TNF-alpha secretion induced by both SDZ MRL 953 and smooth LPS suggests that the monosaccharide and smooth LPS share a receptor or a portion thereof. A pattern of protein tyrosine phosphorylation similar to that induced by LPS was stimulated by the monosaccharide SDZ MRL 953 and SDZ 281.288 and disaccharides lipid IVA, SDZ 880.924, and SDZ 880.611, providing evidence for a common signalling pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683001      PMCID: PMC280797          DOI: 10.1128/iai.61.5.2015-2023.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  SHOCK CAUSED BY GRAM-NEGATIVE MICROORGANISMS. ANALYSIS OF 169 CASES.

Authors:  M H WEIL; H SHUBIN; M BIDDLE
Journal:  Ann Intern Med       Date:  1964-03       Impact factor: 25.391

2.  Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235.

Authors:  F C McIntire; H W Sievert; G H Barlow; R A Finley; A Y Lee
Journal:  Biochemistry       Date:  1967-08       Impact factor: 3.162

3.  Activation and inhibition of Limulus amebocyte lysate coagulation by chemically defined substructures of lipid A.

Authors:  R A Proctor; J A Textor
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

4.  Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant.

Authors:  S Kotani; H Takada; M Tsujimoto; T Ogawa; I Takahashi; T Ikeda; K Otsuka; H Shimauchi; N Kasai; J Mashimo
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

5.  Galactosamine-induced sensitization to the lethal effects of endotoxin.

Authors:  C Galanos; M A Freudenberg; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

6.  Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity.

Authors:  P J Baker; T Hraba; C E Taylor; K R Myers; K Takayama; N Qureshi; P Stuetz; S Kusumoto; A Hasegawa
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

7.  Molecular requirements for B-lymphocyte activation by Escherichia coli lipopolysaccharide.

Authors:  C R Raetz; S Purcell; K Takayama
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

8.  Antagonism of lipopolysaccharide-induced priming of human neutrophils by lipid A analogs.

Authors:  A L Van Dervort; M E Doerfler; P Stuetz; R L Danner
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

9.  Macrophage activation by monosaccharide precursors of Escherichia coli lipid A.

Authors:  M Nishijima; F Amano; Y Akamatsu; K Akagawa; T Tokunaga; C R Raetz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  4 in total

Review 1.  Transcriptional control of the TNF gene.

Authors:  James V Falvo; Alla V Tsytsykova; Anne E Goldfeld
Journal:  Curr Dir Autoimmun       Date:  2010-02-18

2.  Modulation of lipopolysaccharide-induced macrophage gene expression by Rhodobacter sphaeroides lipid A and SDZ 880.431.

Authors:  C L Manthey; P Y Perera; N Qureshi; P L Stütz; T A Hamilton; S N Vogel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 3.  Immunopharmacology of lipid A mimetics.

Authors:  William S Bowen; Siva K Gandhapudi; Joseph P Kolb; Thomas C Mitchell
Journal:  Adv Pharmacol       Date:  2013

4.  Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages.

Authors:  C L Manthey; N Qureshi; P L Stütz; S N Vogel
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.